BeOne Medicines (ONC) Gains Barclays Overweight Rating Ahead of Key 2025 Data Readouts

BeOne Medicines Ltd. (NASDAQ:ONC) ranks among the best biotech stocks to buy. On September 18, Barclays began coverage of BeOne Medicines Ltd. (NASDAQ:ONC), rating it Overweight and setting a price target of $385 on the company’s shares. The firm cited two anticipated “value-inflecting pivotal data readouts” that might propel the oncology company’s growth.

The first projected catalyst is data on BeOne’s BTK inhibitor in first-line mantle cell lymphoma, which is due in the latter half of 2025. Barclays also mentioned that data in first-line gastroesophageal cancer for the company’s PD1 inhibitor with anti-HER2 mixture will come in the fourth quarter of 2025.

Another significant driver for BeOne Medicines Ltd. (NASDAQ:ONC), according to Barclays, is the significance of topline pivotal data for zanidatamab, with or without tislelizumab, in first-line gastroesophageal adenocarcinoma.

BeOne Medicines Ltd. (NASDAQ:ONC) is a global biotechnology company that specializes in oncology medicines, particularly for blood cancers and solid tumors.

While we acknowledge the potential of ONC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.